RhumbLine Advisers
DAWN

RhumbLine Advisers’s Day One Biopharmaceuticals DAWN Stock Holding History

RhumbLine Advisers’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.54M Buy
118,557
+6,878
+6% +$96.9K ﹤0.01% 1734
2025
Q4 		$1.04M Sell
111,679
-10,266
-8% -$85.8K ﹤0.01% 2199
2025
Q3 		$860K Buy
121,945
+5,885
+5% +$40.5K ﹤0.01% 2330
2025
Q2 		$754K Buy
116,060
+34,216
+42% +$235K ﹤0.01% 2394
2025
Q1 		$649K Buy
81,844
+6,291
+8% +$67.8K ﹤0.01% 2397
2024
Q4 		$957K Sell
75,553
-1,747
-2% -$24.3K ﹤0.01% 2275
2024
Q3 		$1.08M Sell
77,300
-8,138
-10% -$116K ﹤0.01% 2233
2024
Q2 		$1.18M Sell
85,438
-4,289
-5% -$62.8K ﹤0.01% 2154
2024
Q1 		$1.48M Buy
89,727
+2,293
+3% +$34.3K ﹤0.01% 2056
2023
Q4 		$1.28M Sell
87,434
-1,769
-2% -$21.4K ﹤0.01% 2138
2023
Q3 		$1.09M Buy
89,203
+22,942
+35% +$299K ﹤0.01% 2154
2023
Q2 		$791K Buy
66,261
+22,265
+51% +$291K ﹤0.01% 2423
2023
Q1 		$588K Buy
43,996
+1,043
+2% +$20.4K ﹤0.01% 2374
2022
Q4 		$924K Buy
42,953
+711
+2% +$14.6K ﹤0.01% 2166
2022
Q3 		$846K Buy
42,242
+8,288
+24% +$176K ﹤0.01% 2233
2022
Q2 		$608K Buy
33,954
+14,546
+75% +$150K ﹤0.01% 2390
2022
Q1 		$193K Buy
+19,408
New +$256K ﹤0.01% 2765

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

RhumbLine Advisers's DAWN Position: Q1 2026 in Review

RhumbLine Advisers increased its Day One Biopharmaceuticals (DAWN) stake by 6.2% in Q1 2026, buying an estimated $96.9K and bringing the position to 118,557 shares worth $2.54M. The position accounts for ﹤0.01% of the portfolio, ranked #1734.

RhumbLine Advisers first reported a position in DAWN in Q1 2022 and has held it in 17 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • RhumbLine Advisers held 118,557 shares of Day One Biopharmaceuticals worth $2.54M as of Q1 2026.
  • RhumbLine Advisers bought 6,878 Day One Biopharmaceuticals shares in Q1 2026, an estimated $96.9K.
  • Day One Biopharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #1734 holding.
  • RhumbLine Advisers first reported a position in Day One Biopharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.